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and 50 years, although SSc is also described in both young and elderly
patients. We conducted the present study to determine if age at disease
onset modulates the clinical characteristics and outcome of SSc patients.
The Spanish Scleroderma Study Group recruited 1037 patients with
a mean follow-up of 5.2 ± 6.8 years. Based on the mean ± 1 standard
deviation (SD) of age at disease onset (45 ± 15 yr) of the whole series,
patients were classiﬁed into 3 groups: age ≤30 years (early onset), age
between 31 and 59 years (standard onset), and age ≥60 years (late onset).
We compared initial and cumulative manifestations, immunologic
features, and death rates. The early-onset group included 195 patients;
standard-onset group, 651; and late-onset, 191 patients. The early-
onset group had a higher prevalence of esophageal involvement (72%
in early-onset compared with 67% in standard-onset and 56% in late-
onset; p = 0.004), and myositis (11%, 7.2%, and 2.9%, respectively;
p = 0.009), but a lower prevalence of centromere antibodies (33%,
46%, and 47%, respectively; p = 0.007). In contrast, late-onset SSc
was characterized by a lower prevalence of digital ulcers (54%, 41%,
and 34%, respectively; p < 0.001) but higher rates of heart conduction
system abnormalities (9%, 13%, and 21%, respectively; p = 0.004).
Pulmonary hypertension was found in 25% of elderly patients and in
12% of the youngest patients (p = 0.010). After correction for the pop-
ulation effects of age and sex, standardized mortality ratio was shown
to be higher in younger patients. The results of the present study con-
ﬁrm that age at disease onset is associated with differences in clinical
presentation and outcome in SSc patients.From Department of Autoimmune Diseases (MAA, GE) and Department
of Epidemiology Medicine (CV), Hospital Clínic, Institut d’Investigacions
Biomèdiques August Pi i Sunyer, Barcelona, Catalonia; Department of Inter-
nal Medicine (CPS, VF), Hospital Vall d´Hebron, Barcelona; Department of
Internal Medicine (LT), Hospital Universitario Central de Asturias, Oviedo,
Asturias; Department of Internal Medicine (MVE), Hospital de Cruces,
Barakaldo, Vizcaya; Department of Internal Medicine (LS), Hospital Uni-
versitario Miguel Servet, Zaragoza; Department of Collagenosis and Pulmo-
nary Hypertension (MJC), Hospital Universitario Virgen del Rocio, Sevilla;
Department of Internal Medicine (JLC), Hospital Universitario San Cecilio,
Granada; Department of Internal Medicine (MTC), Hospital Regional Univer-
sitario Carlos Haya, Málaga; Department of Internal Medicine (CT), Corpo-
ración Sanitaria Universitaria Parc Taulí, Sabadell, Barcelona; Department of
Internal Medicine (JJR), Hospital Universitario La Paz, Madrid; Department
of Internal Medicine (MF), Complejo Hospitalario Universitario de Vigo, Vigo,
Pontevedra; Department of Internal Medicine (JAV), Hospital Universitario
Virgen de las Nieves, Granada, Spain.
Financial support and conﬂicts of interest: This project was funded by an
unrestricted educational scholarship granted by Laboratorios Actelion.
Actelion had no access to the data of the RESCLE Registry database.
The authors have no conﬂicts of interest to disclose.
*See Appendix for members of the RESCLE Registry.
Correspondence: Gerard Espinosa, MD, PhD, Department of
Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia,
Spain (e‐mail: gespino@clinic.ub.es).
Copyright © 2014 by Lippincott Williams & Wilkins
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000000018
Medicine • Volume 93, Number 2, March 2014
Copyright © 2014 Lippincott Williams & Wilkins. Unau(Medicine 2014;93: 73–81)
Abbreviations: ACA = anticentromere antibodies, ACR = American
College of Rheumatology, ANA = antinuclear antibodies, CI =
conﬁdence interval, dcSSc = diffuse cutaneous systemic sclerosis,
FVC = forced vital capacity, IIF = indirect immunoﬂuorescence, ILD =
interstitial lung disease, lcSSc = limited cutaneous systemic sclerosis,
OR = odds ratio, PAP = pulmonary arterial pressure, PH = pulmonary
hypertension, RESCLE = Registro de ESCLErodermia, RP = Raynaud
phenomenon, RR = relative risk, RSHC = right-sided heart catheterization,
SD = standard deviation, SMR = standardized mortality ratio, SSc =
systemic sclerosis, ssSSc = systemic sclerosis sine scleroderma.INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune disease characterized
by extensive ﬁbrosis, vascular dysfunction, and the presence of
several autoantibodies.18,23 The disorder affects the skin and sub-
cutaneous tissue in addition to internal organs, such as lungs,
heart, gastrointestinal tract, and kidneys.18,23 Worldwide, SSc is
more common in women, with a ratio ranging from 3:1 to 14:1.18
Peak age at onset is between ages 20 and 50 years, although
SSc is also described in both young and elderly patients.6,30,37
Age at onset may modulate the clinical expression and as-
sociated prognosis in several autoimmune diseases.2,21,22,35,43
Particularly for SSc, there is inconsistent information regarding
the modifying role of age at onset in baseline and outcome
features.14,25,40,55,57 Some authors have proposed that older patients
with SSc exhibit a different clinical presentation, disease course,
and autoantibody repertory.14,25,40,55,57 Controversies still exist re-
garding the associated mortality rates in relation to age at SSc
onset, with some data pointing out that elderly onset is associ-
ated with poorer prognosis and decreased survival.57
Given the lack of uniform ﬁndings, and given that differ-
ences between older and younger patients would have implications
for prognosis and treatment, we conducted the present study in a
large, well-characterized cohort of 1037 patients with the objec-
tive of determining if age at onset alters the clinical characteristics
and outcome of patients with SSc.PATIENTS AND METHODS
Patients
The current analysis was performed on the frame of the
Spanish Scleroderma StudyGroup (SSSG)49 or RESCLE (Registro
de ESCLErodermia as Spanish nomenclature) Registry. Brieﬂy,
the RESCLE Registry was created by the Spanish Society of
Internal Medicine in 2006 with the aim of compiling a large co-
hort of patients with SSc.49 With the participation of 14 centers
with substantial experience in the management of this disorder,www.md-journal.com 73
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centers obtained ethics committee approval.
To avoid excluding patients with a clear diagnosis of SSc
who did not fulﬁll the American College of Rheumatology (ACR)
preliminary classiﬁcation criteria,3 we also considered the diagno-
sis following a modiﬁcation of the classiﬁcation proposed by
LeRoy and Medsger.31 Demographic, clinical, immunologic, and
capillaroscopic data encompassing 90 variables were collected
according to a standard protocol and then entered into an SPSS
database.
Based on the mean ± 1 standard deviation (SD) of the age at
disease onset of the whole series (45 ± 15 yr), patients were clas-
siﬁed into 3 groups: age ≤30 years (mean − 1 SD) (early-onset
group), age between 31 and 59 years (standard-onset group), and
age ≥60 years (mean + 1 SD) (late-onset group). This distribution
was chosen to maximize age-related differences (early- vs. late-
onset) in addition to having a control group for comparisons
(standard onset, 31–59 yr).Variable Deﬁnitions
We used the following deﬁnitions:
Disease onset: the date of the ﬁrst self-reported symptom (Raynaud
phenomenon [RP] in the majority of patients).
Disease diagnosis: the date when the patient fulﬁlled the ACR
classiﬁcation criteria3,32 or the classiﬁcation proposed by LeRoy
and Medsger.31
Cutaneous subsets that included 4 groups of SSc according
to the extent of skin sclerosis, following a modiﬁcation of the
classiﬁcation proposed by LeRoy and Medsger31: pre-SSc was
established by the presence of RP, puffy ﬁngers, pathognomonic
microvascular alteration detected by capillaroscopy, and/or disease-
speciﬁc autoantibodies but no skin thickening or systemic vascu-
lar features/visceral ﬁbrosis.7 Limited cutaneous SSc (lcSSc) was
considered when skin sclerosis was conﬁned distally to the
elbows and knees or the face. Diffuse cutaneous SSc (dcSSc)
was considered when skin thickening extended proximally to
the elbows and knees or included the trunk; and systemic sclerosis
sine scleroderma (ssSSc) was deﬁned by the presence of RP, typ-
ical vascular features, visceral ﬁbrosis, and speciﬁc positive anti-
nuclear antibodies (ANA) without skin sclerosis.41
Peripheral vascular manifestations: deﬁned by the presence of
RP with or without ischemic digital ulcers. Acro-osteolysis
(bony resorption of the terminal digital tufts secondary to ische-
mia) and telangiectasias were also recorded under this category.
Gastrointestinal tract involvement: including any of the following
diagnoses considered related to SSc: esophageal involvement,
when hypomotility of the lower two-thirds of the esophagus and/
or decreased peristalsis were conﬁrmed by manometry or cine-
radiographic study; gastric involvement, when gastric hypomotility
was detected by radiographic or radionuclide study or when gastric
antral vascular ectasia was identiﬁed by endoscopy; intestinal in-
volvement, when an intestinal motility disturbance was conﬁrmed
bymanometry or cine-radiographic study, whenmalabsorption syn-
drome was diagnosed by breath test, or when intestinal pseudo-
obstruction was identiﬁed by simple radiology or computerized
tomography scan. Diagnoses of primary biliary cirrhosis, autoim-
mune hepatitis, or nodular regenerative hyperplasia of the liver
were encompassed under the term hepatic involvement.
Pulmonary involvement: deﬁned by the presence of interstitial
lung disease (ILD) or pulmonary hypertension (PH). The former
was established if any of the following criteria were identiﬁed:
a) restrictive pulmonary pattern with forced vital capacity (FVC)
below 70% of expected value on pulmonary function tests, b) pul-
monary interstitial pattern evidenced by chest radiograph or high-74 www.md-journal.com
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by bronchoalveolar lavage (deﬁned as neutrophilia of≥3%, eosin-
ophilia of ≥2%, or lymphocytosis ≥15%).4,5 FVC level below
70%was selected because of its association with poorer prognosis
in SSc patients.47 PH was diagnosed when systolic pulmonary ar-
terial pressure (PAP) was estimated to be>40 mmHg by Doppler
echocardiogram corresponding to maximum tricuspid regurgitant
jet velocity of 3.0–3.5 m/s or when mean PAP was found to be
equal or higher than 25 mm Hg at rest by right-sided heart cathe-
terization (RSHC).19
Heart involvement: established by 1 or more of the following:
pericarditis, ischemic cardiomyopathywith no known cause, revers-
ible thallium perfusion defects after cold stimulation, any distur-
bance on color-Doppler echocardiography, electrocardiographic
abnormalities with no other cause, left ventricular ejection fraction
lower than 50%, or right ventricular ejection fraction lower than
40% on echocardiography or radionuclide ventriculography.
Muscle involvement: myopathy was established by the presence
of proximal muscle weakness or myalgias and serum creatine ki-
nase levels over the normal value in addition to characteristic
results of electromyography (EMG) and nerve conduction studies.
Calcinosis was deﬁned as widespread soft-tissue calciﬁcation or in
a localized area causing secondary muscle atrophy, joint contractures
or skin ulceration.
Joint involvement: deﬁned by the presence of arthralgia, tendon
friction rubs, or arthritis (concomitant erosion and joint space
narrowing).8
Scleroderma renal crisis: deﬁned by the presence of a rapid dete-
rioration of renal function (with concomitant normal urine sedi-
ment) within a period of less than 1 month in the absence of
previous evidence of signiﬁcant kidney disease or by the combina-
tion of abrupt onset or aggravation of moderate to severe arterial
hypertension (>160/90 mm Hg) accompanied by manifestations
of malignant hypertension (hypertensive grade III or IV retinopa-
thy, pulmonary edema and/or hypertensive encephalopathy) and
elevation of peripheral renin activity to at least twice the upper
limit of normal.53
Sicca syndrome: deﬁned when ocular and oral dryness was present
with ocular signs or abnormal tests of salivary gland function or
abnormalities in salivary gland biopsy.
Nailfold capillaroscopy: 2 main capillaroscopic patterns were dis-
tinguished34: a) active pattern characterized by predominant capil-
lary loss, and b) slow pattern characterized by the presence of
megacapillaries but no signiﬁcant capillary loss.
Immunologic features: including ANA identiﬁed by indirect im-
munoﬂuorescence (IIF) assay using Hep-2 cell lines or by IIF using
triple tissue cryostat section (liver-stomach-kidney). Anticentromere
antibodies (ACA), anti-PM-Scl, and antibodies to extractable nu-
clear antigens (SSA/Ro, SSB/La, Sm, RNP, and topoisomerase I
[Scl-70]) were also determined.
Mortality: The standardizedmortality ratio (SMR) was calculated.
This is the measure used to assess the relative mortality of a dis-
ease in comparison with the general population. SMR was calcu-
lated according to the method described by Breslow and Day10
with speciﬁcmortality data (1986–2010) obtained from the Spanish
Statistics National Institute.Statistical Analysis
This study is a nationwide, cross-sectional analysis of age
groups. Results from continuous variables are presented as mean ±
SD, and categorical data as percentages. Statistical evaluation was
performed using a contingency table test (chi-square test) to identify
signiﬁcant differences or associations among the 3 age groups
for qualitative variables. ANOVA and t-test was used for© 2014 Lippincott Williams & Wilkins
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TABLE 1. Demographic, Clinical, and Immunologic
Characteristics of 1037 Patients With SSc*
Characteristic No. (%)
Sex, male/female (%) 130/907 (22/88)
Age at disease onset, mean±SD (yr) 45±15
Age at diagnosis, mean±SD (yr) (n=1022) 51±15
Time of follow-up, mean ± SD (yr) 5.2±6.8
Death 151 (14.6)
SSc-related (n=151) 78 (51.7)
Type of scleroderma (n=1035)
Limited cutaneous SSc 623 (60.2)
Diffuse cutaneous SSc 270 (26.1)
SSc sine scleroderma 90 (8.7)
Pre-SSc 52 (5.0)
First manifestation (n=939)
Raynaud phenomenon 787 (83.8)
Arthralgia 54 (5.8)
Cumulative clinical manifestations
Peripheral vascular manifestations
Raynaud phenomenon (n=1037) 967 (93.2)
Telangiectasies (n=1036) 629 (60.7)
Digital ulcers (n=1036) 435 (41.9)
Osteomuscular manifestations
Calcinosis (n=980) 193 (19.7)
Arthritis (n=927) 173 (18.7)
Myositis (n=928) 66 (7.1)
Digestive tract involvement
Esophagus (n=922) 608 (65.9)
Lung involvement
Interstitial lung disease (n=983) 499 (50.8)
Pulmonary arterial hypertension (n=881) 167 (18.9)
Heart involvement
Conduction alteration (n=872) 118 (13.5)
Ischemia (n=871) 94 (10.8)
Pericarditis (n=873) 46 (5.3)
Renal involvement
Scleroderma renal crisis (n=870) 29 (3.3)
Other manifestations
Sicca syndrome (n=980) 328 (33.5)
Peripheral neuropathy (n=155) 18 (11.6)
Immunologic features
Antinuclear antibodies (n=1029) 906 (88.0)
Anticentromere antibodies (n=913) 398 (43.6)
Anti-topoisomerase I (n=910) 202 (22.2)
*All data derived from 1037 patients except when indicated.
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tion of multiple comparisons. Values of p < 0.05 were considered
signiﬁcant. Survival curves were calculated using the Kaplan-
Meier method, and the log rank ratio was used to identify dif-
ferences. Multivariate Cox regression analysis was performed
to identify independent variables related to diminished survival.
Logistic regression was used to determine the risk of SSc major
organ involvement (ILD, PH, scleroderma renal crisis, heart in-
volvement, and digital ulcer) as a function of age at SSc onset.
Adjustment was done for sex, cutaneous subtype of SSc, and
presence of anti-Scl-70 or ACA.
For SMR calculation, indirect standardization was per-
formed using year-speciﬁc population rates for Spain. Conﬁdence
intervals (CI) for the SMR were calculated using the assumption
that the observed number of cases followed a Poisson distribution.
All statistical analyses were performed with SPSS 18.0 for
Windows (Chicago, IL).
RESULTS
General Characteristics
The whole cohort comprised 1037 patients (88% women)
with a mean follow-up of 5.2 ± 6.8 years. Mean age at disease
onset was 45 ± 15 years. LcSSc was the most prevalent subtype
(n = 623, 60%), and RP was the most common initial disease
manifestation (84%). Table 1 shows the demographic andmain cu-
mulative manifestations of the cohort. Table 2 presents the demo-
graphic, initial presentation, and immunologic features; Table 3
compares the prevalence of cumulative clinical characteristics of
the SSc patients according to their age at onset.
Early-Onset SSc Group
Patients in the early-onset group were characterized by a
longer interval (in years) from disease onset to diagnosis (12.0 ±
13.0 yr vs. 5.8 ± 7.8 in patients with standard onset and 2.4 ±
3.6 in those with late-onset SSc, p < 0.001) (see Table 2). Com-
pared with elderly patients and considering cumulative organ
damage, patients with early-onset SSc more frequently had
myositis (11% vs. 7.2% vs. 2.9%, p = 0.009) and esophageal
involvement (72% vs. 67% vs. 56%, p = 0.004) (see Table 3).
Pre-scleroderma was more frequent in these patients (9.7%
vs. 4.3% vs. 2.6%, p = 0.002). Regarding antibody proﬁle,
patients with early onset of SSc had lower prevalence of ACA
than patients with standard onset and those with late onset of
SSc (33% vs. 46% vs. 47%, respectively, p = 0.007).
Late-Onset SSc Group
Elderly patients had a higher prevalence of lcSSc (67.5% vs.
51% for early onset vs. 60.5% for standard onset, p = 0.004), a
lower frequency of digital ulcers (34% vs. 54% vs. 41%, respec-
tively, p< 0.001) and a higher prevalence of heart conduction sys-
tem disorders (21% vs. 9% vs. 13%, respectively, p = 0.004) in
addition to systemic hypertension (13% vs. 35% vs. 68%, p <
0.001) (see Tables 2 and 3). Patients with late-onset disease had
an increased prevalence of PH (diagnosed by echocardiography)
documented in 25%, compared to 12% in the youngest patients
and 19% in the group of patients aged 31–59 years (p = 0.010).
By this technique the mean systolic PAP was 41 ± 21 mm Hg
for the elderly group vs. 31 ± 18 for the younger patients
(p = 0.006). The prevalence of PH diagnosed by RSHC
(performed in 56 patients: 7 in early onset, 41 for the group aged
31–59 yr, and 8 in the late-onset group) was not different between
the 3 groups (see Table 3).© 2014 Lippincott Williams & Wilkins
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To analyze the independent effect of age on major organ in-
volvement observed in the previous groups, multivariate analysis
with logistic regression was performed. Relationships between
age at diagnosis and ILD (p < 0.001; odds ratio [OR], 1.02; 95%
CI, 1.01–1.03), PH (p < 0.001; OR, 1.02; 95% CI, 1.01–1.03),
heart disease (p < 0.001; OR, 1.03; 95% CI, 1.02–1.04) and dig-
ital ulcer (p < 0.001; OR, 0.98; 95% CI, 0.97–0.99) were signif-
icant. The relationship between age at diagnosis and scleroderma
renal crisis was not signiﬁcant.
Differences among the 3 groups were not found in sex distri-
bution, ﬁrst clinical manifestation, nailfold capillaroscopy pattern,www.md-journal.com 75
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TABLE 2. Demographic Characteristics and Serologic Proﬁles, by Age of SSc Onset*
Group 1
(≤30 yr)
(n=195)
Group 2
(31–59 yr)
(n=651)
Group 3
(≥60 yr)
(n=191) P
P ≤30 vs.
31–59
P ≤30 vs.
≥60
P 31–59 vs.
≥60
Sex (female, %) 178 (91.3) 561 (86.2) 168 (87.9) 0.164
Age at disease onset, mean±SD (yr) 22±5.8 45±8.1 67±5.9
Time from onset to diagnosis,
mean±SD (yr) (n=1022)
12±13 5.8±7.8 2.4±3.6 <0.001 <0.001 <0.001 <0.001
Follow-up, mean±SD (yr) 6.5±8.3 5.3±6.7 3.6±4.7 <0.001 0.073 0.007 <0.001
Deaths 19 (9.7) 97 (14.9%) 35 (18.3%) 0.053
Type of scleroderma (n=1035)
Limited cutaneous SSc 100 (51.3) 394 (60.5) 129 (67.5) 0.004 0.058 0.003 0.212
Diffuse cutaneous SSc 51 (26.2) 179 (27.5) 40 (20.9) 0.201
SSc sine scleroderma 25 (13) 49 (7.5) 16 (8.4) 0.071
Pre-SSc 19 (9.7) 28 (4.3) 5 (2.6) 0.002 0.007 0.004 1.000
First manifestation (n=939)
Raynaud phenomenon 154 (88.0) 492 (84.0) 141 (78.0) 0.134
Puffy hands 4 (2.3) 11 (1.9) 5 (2.9) —
Arthralgia 10 (5.7) 36 (6.1) 8 (4.5) 0.718
Capillaroscopy
Slow pattern (n=707) 75 (54.0) 254 (57.0) 59 (48.0) 0.217
Active pattern (n=707) 44 (31.0) 140 (32.0) 46 (38.0) 0.407
Immunologic features
Antinuclear antibodies (n=1029) 174 (90.0) 570 (88.0) 162 (85.0) 0.327
Scl-70 (n=910) 43 (25.0) 128 (22.0) 31 (20.0) 0.604
Centromeric (n=913) 54 (33.0) 268 (46.0) 76 (47.0) 0.007 0.010 0.021 1.000
Pm-Scl (n=426) 5 (5.4) 13 (5.0) 2 (2.8) —
Rheumatoid factor (n=644) 35 (30.0) 83 (21.0) 35 (29.0) 0.045 0.122 1.000 0.191
Ro (n=892) 19 (11.0) 72 (13.0) 22 (13.0) 0.878
La (n=885) 6 (3.7) 16 (2.8) 4 (2.5) —
RNP (n=870) 12 (7.6) 28 (5.1) 5 (3.1) 0.192
IgG anticardiolipin (n=489) 10 (11) 23 (7.4) 8 (9.5) 0.560
IgM anticardiolipin (n=489) 1 (1.1) 4 (1.3) 0 (0) —
*All data derived from 1037 patients except when indicated; percentages in (%).
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peripheral nerves.Mortality
During follow-up, 151 patients (14.6%) died. Cause of death
was identiﬁed in 122 of the 151 patients and included pulmonary
involvement in 61 (PH in 25, ILD in 19, and both in 17), cancer in
18, scleroderma renal crisis in 13, sepsis in 5, ischemic heart dis-
ease in 4, and other causes (stroke, chronic renal failure, chronic
obstructive pulmonary disease, lethal arrhythmias, or pulmonary
embolism) in 21. In 78 (63.9%) of these cases, the cause of death
was considered directly related to SSc. On multivariate analysis,
independent variables related to increased mortality were dcSSc
(p = 0.001; relative risk [RR], 2.22; 95%CI, 1.39–3.58), age at di-
agnosis (p =< 0.001; RR, 1.05; 95% CI, 1.04–1.07), FVC< 70%
(p = 0.008; RR, 1.79; 95% CI, 1.17–2.76), PH (p = 0.003; RR,
1.89; 95% CI, 1.24–2.86), and scleroderma renal crisis (p = <
0.001; RR, 6.16; 95% CI, 2.90–13.1). Differences between the
early- and late-onset groups in relation to the speciﬁc causes of
death were not found.
The overall cohort median survival time from diagnosis
was 21.9 years, and the overall 5-year survival rate was 90.7%.
The Kaplan–Meier survival curves were signiﬁcantly different76 www.md-journal.com
Copyright © 2014 Lippincott Williams & Wilkins. Unau(p< 0.0001) for the 3 groups of patients (Figure 1), with a median
survival time of 29.3 years in patients aged ≤30 years, 21.9
for those aged 31–59, and 12.2 years in the elderly patients. As
there is some controversy regarding deﬁnitions of disease dura-
tion for patients with SSc, we performed sensitivity analyses
using Kaplan-Meier curves to estimate if survival changes when
a non-Raynaud symptom was used instead of RP. Results of this
analysis did not indicate any difference (data not shown).
The SMR of the whole cohort calculated for a period of
24 years from 1986 to 2010 was 3.80 (95% CI, 3.18–4.43)
compared with the background population. After correction
for the population effects of age and sex, higher SMR values
were found in younger patients aged ≤30 years (26.22; 95% CI,
14.43–38.01), followed by patients aged 31–59 years (13.32;
95% CI, 10.55–16.08). The lowest SMR was found in older
patients ≥60 years (1.78; 95% CI, 1.17–2.39).DISCUSSION
In this large cohort of Spanish patients, we conﬁrmed that the
age at disease onset inﬂuences the clinical manifestations, major
organ involvement, and outcome of patients with SSc. Late-
onset SSc was characterized by an elevated prevalence of lcSSc
with high cardiopulmonary morbidity manifested as PH, heart© 2014 Lippincott Williams & Wilkins
thorized reproduction of this article is prohibited.
TABLE 3. Cumulative Clinical Manifestations in Patients by Age of Onset of SSc*
Group 1
(≤30 yr)
(n=195)
Group 2
(31–59 yr)
(n=651)
Group 3
(≥60 yr)
(n=191) P
P ≤30 vs.
31–59
P ≤30 vs.
≥60
P 31–59 vs.
≥60
Peripheral vascular manifestations
Raynaud phenomenon 186 (95.0) 605 (93.0) 176 (92.0) 0.390
Digital ulcers (n=1036) 106 (54.0) 265 (41.0) 64 (34.0) <0.001 0.002 <0.001 0.216
Telangiectasies (n=1036) 117 (60.0) 391 (60.0) 121 (63.0) 0.710
Acro-osteolysis (n=966) 19 (10.0) 53 (8.7) 13 (7.3) 0.538
Osteomuscular
Calcinosis (n=980) 39 (22.0) 125 (20.0) 29 (16.0) 0.257
Arthritis (n=927) 26 (16.0) 114 (19.0) 33 (19.0) 0.564
Myositis (n=928) 19 (11.0) 42 (7.2) 5 (2.9) 0.009 0.171 0.006 0.155
Tendon friction rubs (n=927) 7 (4.2) 27 (4.6) 12 (6.9) 0.432
Digestive involvement
Esophagus (n=922) 118 (72.0) 393 (67.0) 97 (56.0) 0.004 0.608 0.005 0.022
Stomach (n=920) 22 (14.0) 82 (14.0) 25 (15.0) 0.974
Malabsorption (n=769) 10 (7.9) 26 (5.3) 10 (6.5) 0.535
Heart involvement
Pericarditis (n=873) 7 (4.7) 28 (5.1) 11 (6.4) 0.749
Ischemia (n=871) 16 (11.0) 62 (11.0) 16 (9.2) 0.763
Conduction alteration (n=872) 13 (8.7) 69 (13.0) 36 (21.0) 0.004 0.674 0.005 0.016
Lung involvement
ILD (n=983) 88 (50.0) 305 (49.0) 106 (57.0) 0.139
Ground-glass pattern (n=506) 35 (35.0) 113 (36.0) 24 (26.0) 0.202
Reticular pattern (n=887) 34 (22.0) 130 (23.0) 32 (19.0) 0.554
PH by echocardiogram† (n=881) 18 (12.0) 106 (19.0) 43 (25.0) 0.010 0.165 0.007 0.185
PH by RSHC‡ (n=56) 6 (86.0) 34 (83.0) 7 (88.0) 0.940
Isolated PAH (without ILD) (n=167) 2 (11.0) 8 (7.5) 6 (14.0) —
Renal involvement
Scleroderma renal crisis (n=870) 5 (3.4) 19 (3.4) 5 (2.9) —
Other manifestations
Peripheral neuropathy (n=155) 5 (15.0) 11 (11.0) 2 (8.3) —
Sicca syndrome (n=980) 51 (29.0) 210 (34.0) 67 (36.0) 0.343
Systemic hypertension (n=170) 5 (13.0) 36 (35.0) 19 (68.0) <0.001 0.039 <0.001 0.002
Abbreviations: PAH = pulmonary arterial hypertension.
*All data derived from 1037 patients except when indicated; percentages in (%)
†Systolic pulmonary arterial pressure ≥40 mm Hg.
‡Mean pulmonary artery pressure ≥25 mm Hg.
Medicine • Volume 93, Number 2, March 2014 Early- versus Late-Onset Systemic Sclerosisdisease, and systemic hypertension. This elderly group suffered
less frequently from digital ulcers and had higher probability of
being positive for ACA.
In previous studies, the cut-off for deﬁning late-onset SSc
ranged from 55 to 75 years. Taking into account this data, similar
features in this subgroup of patients such as raised prevalence
of cardiovascular and lung involvement have been previously
reported.25,33,40,55,57 In these previous studies, higher prevalence
of PH, systemic arterial hypertension, abnormal diastolic func-
tion, and conduction system alterations were the most striking
ﬁndings. Although the prevalence of PH in the current study
was at the lower range (25%) of the spectrum (35%–45%) of pre-
viously reported data,25,33,46 right heart catheterization was per-
formed in only 56 patients in the present series. This precludes
comparisons because many possible causes of elevated estimations
in right ventricular systolic pressure already exist. Systemic arte-
rial hypertension, diastolic dysfunction, and conduction abnor-
malities, all more prevalent in the late-onset group, can lead to© 2014 Lippincott Williams & Wilkins
Copyright © 2014 Lippincott Williams & Wilkins. Unauleft ventricular hypertrophy and thus to nonspeciﬁc elevation of
pulmonary pressure.25,44 We are aware that Doppler echocardiog-
raphy may be misleading in the assessment of patients with
suspected PH, as measurement of pulmonary artery systolic pres-
sure by ultrasound can over- and underestimate true PAP.
Our data did not allow us to determine whether the higher
frequency of conduction blocks in the late-onset group was due
to SSc (cardiac ﬁbrosis) or was related to the normal aging pro-
cess. It is known that heart conduction system abnormalities and
electrocardiographic changes increase with age,17,42 and that
among people aged >65 years the prevalence of electrocardio-
graphic abnormalities is approximately 30%.17,42 In addition, a
possible bias related to differences in diagnostic workup can not
be excluded, as older SSc-patients may be getting electrocardiograms
more frequently than younger patients as part of their regular
medical assessments.
The accompanying lower prevalence of digital ulcers and
higher frequency of ACA found in the older patients are inwww.md-journal.com 77
thorized reproduction of this article is prohibited.
FIGURE 1. Kaplan-Meier estimate of the probability of death
(since diagnosis) depending on age at disease onset.
Alba et al Medicine • Volume 93, Number 2, March 2014accordance with results from other groups.25,33,50,52,55 Why older
patients had a lower prevalence of digital ulcer is unknown. We
suggest that the SSc-cutaneous subset and the presence of spe-
ciﬁc autoantibodies are of relevance. Previous studies13,50,52 have
raised the possibility that speciﬁc autoantibodies are related to
more severe peripheral vascular disease. The prevalence and the
time elapsed for the development of digital ulcers were different
in anti-Scl-70 and ACA-positive patients—that is, anti-Scl-70 was
related to a higher prevalence of digital ulcers and the appearance
of the ﬁrst ulcer occurred a mean of 6 years earlier compared to
ACA patients. In addition, the former patients were younger at
the onset of ﬁrst RP symptoms and had shorter time periods from
the onset of RP to the ﬁrst digital ulcer, probably reﬂecting more
severe vascular disease.13,50,52 Diffuse skin sclerosis has been as-
sociated as an independent risk factor for the development of dig-
ital ulcer.50,52 Higher grade of sclerosis of the ﬁngers and hands
related to dcSSc probably impedes blood ﬂow and wound healing
and favors the formation of digital ulcers.51 In the current study,
the late-onset group was characterized by a higher prevalence of
ACA and lcSSc, and, therefore, probably a milder peripheral vas-
cular involvement. Other factors that probably play a role include
the normal immune system senescence, aging-related changes of
the skin’s microcirculation, more cold avoidance among the elderly,
and the fact that older patients are more likely to be on aspirin and
calcium channel blockers for comorbidities.
In contrast to these referred similarities, we were unable to
ﬁnd an increased frequency of renal involvement and sicca syndrome
in patients with late-onset SSc.33,40 One explanation for these
discrepancies may be the criteria that we used to deﬁne SSc-
related manifestations. We considered only scleroderma renal cri-
sis as renal manifestation of SSc, whereas in the study by Manno
et al,33 an elevation of creatinine levels beyond 1.3 mg/dL or>2+
protein in urine dipstick was considered to be kidney involvement
in their SSc patients.
We note that patients with late onset were diagnosed faster
that younger patients, an observation made also in other cohorts.33,40
We speculate that the higher prevalence of extracutaneous in-
volvement at disease onset and the earlier appearance of systemic
manifestations (particularly lung and heart involvement) in the
elderly allow early identiﬁcation and diagnosis.33,40 The more fre-
quent medical assessments performed in older patients as part of
the standard of care for common chronic disorders could also play
a role. On the other hand, delayed diagnosis in younger patients78 www.md-journal.com
Copyright © 2014 Lippincott Williams & Wilkins. Unaumay be secondary to the misclassiﬁcation of RP as a primary con-
dition, in particular when nailfold capillary microscopy and spe-
ciﬁc autoantibody tests are not available.29 Finally, there could
be a subgroup of young patients with pre-SSc or ssSSc with milder
manifestations who are initially classiﬁed as having undifferenti-
ated connective tissue disease (UCTD) but later develop features
of deﬁnite SSc.54
We are aware that some of the differences that we and
others25,33,40,46,55,57 have found in older patients with SSc could
be related to the normal aging process and concurrent related
diseases. Aging is associated with several physiologic adaptations
and an increased susceptibility to several diseases. Older age is
related to large artery stiffening9,39 that increases the risk for sys-
temic hypertension and left ventricle hypertrophy.20 Valve calciﬁ-
cation and thickening28 may predispose older patients to cardiac
conduction problems.28 Additionally, not only does systemic vas-
cular resistance increase with age, but pulmonary vascular resis-
tance is also increased, probably due to reduced compliance of
the pulmonary vascular bed.45,46
In contrast to the similar clinical and immunologic features
reported for late-onset presentation, early-onset SSc is less well
characterized.25,33,40,55 In previously reported cohorts,25,33,40,55
patients were grouped based on an age limit higher or lower than
60–75 years, and therefore they lost the characteristics of the
youngest patients. In the present study, we described for the ﬁrst
time that patients with early-onset disease (mean age, 25 ± 5.8 yr)
presented more frequently with esophageal involvement and
myositis. Previously, Manno et al33 reported that gastrointesti-
nal involvement was more common in patients aged younger
than 65 years, and Weng et al57 observed higher levels of creatine
kinase in the group of patients aged 19–38 years; although this lat-
ter group did not have a higher prevalence of myopathy.
Our results from the group of early-onset SSc are in accor-
dance with results from the European League Against Rheuma-
tism Scleroderma Trial and Research (EUSTAR) database.16 In
that study of adult patients with disease onset between the ages
of 20 and 40 years (mean age, 32 yr), lcSSc was found in 53%
(51% in the current series), RP in the same frequency as our
patients (95%), esophageal involvement in 65% (72% in our se-
ries), digital ulcers in 41% (54% in our series), pulmonary ﬁbrosis
in 36% (50% in our series), and pulmonary arterial hypertension
in 14% (12% in our patients). ANAwere present in 92.8% com-
pared with 90% in the present series, topoisomerase-I antibodies
were positive in 40.7% (25% in our series), and ACA in 27.8%
(33% in our series). Features of this group of young patients with
arthralgia, muscle involvement, dysphagia, and lower frequency
of ACA resemble some of the main characteristics of juvenile
SSc.36,58 More studies are needed to clarify the clinical proﬁle
of the younger adult patients with SSc.
Although large geographic variations in SSc prevalence and
incidence have been described,12 there was no clear regional trend
with regard to organ involvement.56 The prevalence of both ﬁrst
and cumulative clinical manifestations of our population of Span-
ish patients with SSc is very similar to those described in other
registries from the same geographic zone such as the EUSTAR
database.55
Finally, we conﬁrmed that mortality is increased in SSc
patients compared with an age- and sex-matched population. The
SMR of the whole RESCLE cohort was 3.80 (95% CI, 3.18–4.43).
Notably, it was calculated for a period of 24 years (1986–2010),
supporting comparability to other studies made within the same
period for different populations. The SMR of our series was higher
than that reported in Australia24 (1.46) and Denmark27 (2.9), but
similar to the SMR of 3.9 from China,38 4.0 from the United
Kingdom,11 4.2 from Spain,47 and 4.7 from Canada.1 Two recent© 2014 Lippincott Williams & Wilkins
thorized reproduction of this article is prohibited.
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expected, patients with late-onset SSc had the highest mortality
rate. However, when we compared SMRs of patients with SSc
with the general Spanish population in the same period, higher
SMRs were found in patients aged ≤30 years (SMR 26.22; 95%
CI, 14.43–38.01), followed by patients aged 30–59 years (SMR
13.32; 95% CI, 10.55–16.08). It is noteworthy that the lowest
SMR was found in the elderly patients.
The overall 5-year survival rate reported in the present se-
ries (90%) was similar to that previously reported by other
authors.15,25,27,37,40 The cause of death was considered directly at-
tributable to SSc in 64% of cases, most of these secondary to lung
involvement. As previously reported,47,48 we identiﬁed age at di-
agnosis, cutaneous subset, lung involvement, and scleroderma re-
nal crisis as independent prognostic factors that inﬂuence survival.
Strengths of the present study include the large number of
patients derived from the same geographic location as well as
the multiple analyses and corrections made for exploring the ef-
fect of age on SSc manifestations. Limitations of the present study
include missing information concerning time to development of
each manifestation (systemic manifestations seemed to appear
earlier in older patients according to previous series25,33,40,55,57)
and treatment modalities. Also, the limited number of patients
with RSHC precludes determining the real prevalence of pulmo-
nary arterial hypertension. In addition, the absence of a control
group of young and elderly matched populations without SSc is
important because some of the differences observed could be
due to the normal aging process. Finally, as in all registry studies,
the accuracy of the clinical diagnosis as judged by the attending
physician can not be veriﬁed.
In spite of these limitations, the present study suggests that
age at onset is associated with differences in clinical presenta-
tion and outcome in patients with SSc. Knowledge of these dif-
ferent characteristics can help to improve the management of
the disease.
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APPENDIX
RESCLE Registry
RESCLE Registry Members: Alba MA (Hospital Clínic,
Barcelona, Spain), Alonso M (Complejo Hospitalario Universitario
de Vigo, Vigo, Spain), Bernardino J (Hospital Universitario Cen-
tral de Asturias, Oviedo, Spain), Bernardo J (Hospital Universitario
Central deAsturias, Oviedo, Spain), Callejas JL (Hospital Universitario
San Cecilio, Granada, Spain), Camps MT (Hospital Regional
Universitario Carlos Haya, Málaga, Spain), Castillo MJ (Hos-
pital Universitario Virgen del Rocio, Sevilla, Spain), Eguiluz
S (Hospital de Cruces, Barakaldo, Spain), Egurbide MV (Hos-
pital de Cruces, Barakaldo, Spain), Espinosa G (Hospital
Clínic, Barcelona, Spain), Fonollosa V (Hospital Vall d´Hebron,
Barcelona, Spain), Freire M (Complejo Hospitalario Univer-
sitario de Vigo, Vigo, Spain), García FJ (Hospital Universitario
Virgen del Rocio, Sevilla, Spain), Gil A (Hospital Universitario
La Paz, Madrid, Spain), González R (Hospital Universitario Virgen
del Rocio, Sevilla, Spain), Guillén A (Hospital Vall d´Hebron,
Barcelona, Spain), Marí B (Corporación Sanitaria Universitaria© 2014 Lippincott Williams & Wilkins
Copyright © 2014 Lippincott Williams & Wilkins. UnauParc Taulí, Sabadell, Spain), Martín N (Hospital Universitario
La Paz, Madrid, Spain), Pérez I (Hospital Regional Universitario
Carlos Haya, Málaga, Spain), Ríos JJ (Hospital Universitario La
Paz, Madrid, Spain), Ríos R (Hospital Universitario San Cecilio,
Granada, Spain), Rodríguez M (Hospital Universitari Mútua
Terrassa, Terrassa, Spain), Ruiz M (Hospital Universitario San
Cecilio, Granada, Spain), Sáez L (Hospital Universitario Miguel
Servet, Zaragoza, Spain), Simeón CP (Hospital Vall d´Hebron,
Barcelona, Spain), Soto A (Complejo Hospitalario Universitario
de Vigo, Vigo, Spain), Tolosa C (Corporación Sanitaria Univer-
sitaria Parc Taulí, Sabadell, Spain), Trapiella L (Hospital Univer-
sitario Central de Asturias, Oviedo, Spain), Vargas JA (Hospital
Universitario Virgen de las Nieves, Granada, Spain), Vallejo C
(Hospital Universitario Miguel Servet, Zaragoza, Spain), Velilla J
(Hospital Universitario Miguel Servet, Zaragoza, Spain).
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